Modern Pathology Editor in Chief discusses with Laura Wood MD PhD her recent study on quantitative assessment of residual pancreatic intraductal carcinoma following neoadjuvant chemotherapy. The implications of finding that the intraductal component of pancreatic cancer is more resistant to chemotherapy are highlighted.

Associated article: Intraductal pancreatic cancer is less responsive than cancer in the stroma to neoadjuvant chemotherapy

https://www.nature.com/articles/s41379-020-0572-6